Laia Lorenzo-Esteller

Dr. Laia Lorenzo-Esteller

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
LLLaia Lorenzo-Esteller
Laia Lorenzo-Esteller
RPRaúl Ramos Polo
Raúl Ramos Polo
APAlexandra Pons-Riverola
Alexandra Pons-Riverola
HCHerminio Morillas Climent Climent
Herminio Morillas Climent Climent
JBJavier Berdejo
Javier Berdejo
PMPedro Moliner
Pedro Moliner
Pericardial disease is increasingly recognized in cancer patients, including acute pericarditis, pericardial effusion, and constrictive pericarditis, often indicating a poor prognosis. Acute pericarditis arises from direct tumor involvement, cancer therapies, and radiotherapy. Immune checkpoint inhibitor (ICI)-related pericarditis, though rare, entails significant mortality risk. Treatment includes NSAIDs, colchicine, and corticosteroids or anti-IL1 drugs in refractory cases. Pericardial effusion is the most frequent manifestation, primarily caused by lung cancer, followed by breast cancer, lymphoma, leukemia, gastrointestinal tumors, and melanoma. Chemotherapy, immunotherapy, and radiotherapy may also cause fluid accumulation in the pericardial space. Symptomatic relief for pericardial effusion may require pericardiocentesis, prolonged catheter drainage, or a pericardial window. Instillation of intrapericardial cytostatic agents may reduce recurrence. Constrictive pericarditis, though less common, often develops from radiotherapy and requires multimodality imaging for diagnosis, with pericardiectomy as the definitive treatment. Primary pericardial tumors are rare, with metastases being more frequent. Patients with cancer and pericardial disease generally have poor survival, emphasizing the need for early detection. A multidisciplinary approach involving hematologists, oncologists, and cardiologists is crucial to tailoring pericardial disease treatment to a patient’s clinical status, thereby improving the quality of life and prognosis.

Verified
Journal Article
Open access
PDF file
ALAinhoa Lorenzo
Ainhoa Lorenzo
RPRaúl Ramos Polo
Raúl Ramos Polo
LLLaia Lorenzo-Esteller
Laia Lorenzo-Esteller
XLXinying Lin
Xinying Lin
EBEmma Barragan
Emma Barragan
JCJosep Comín-Colet
Josep Comín-Colet
Heart failure (HF) is becoming increasingly common, especially in older females, and displays marked sex-related differences in pathophysiology, treatment, and outcomes. Submaximal exercise capacity (SEC), frequently measured by the six-minute walk test (6MWT), is an important marker of aerobic function, prognosis, and quality of life in HF. However, evidence regarding sex differences in SEC remains limited and inconsistent. This single-centre, prospective cohort study included 1069 patients with chronic HF enrolled between 2004 and 2014. SEC was assessed using the 6MWT, and extensive clinical and psychosocial data were collected. Multivariate models evaluated the independent association between sex and SEC. Results showed that females had significantly shorter 6MWT distances (155 ± 149 m) than males (265 ± 164 m; p < 0.001). Female sex was an independent predictor of impaired SEC in both unadjusted and adjusted analyses (odds ratios 2.226–3.609; p < 0.001). Additional determinants of reduced SEC included advanced age, higher NYHA class, elevated heart rate, diabetes, iron deficiency, dependence in activities of daily living, cognitive impairment, and depressive symptoms. These findings demonstrate that female sex is a strong, independent predictor of reduced functional capacity in chronic HF and emphasize the need for sex-specific strategies addressing both clinical and psychosocial factors to improve outcomes.

14 April 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
JMJosep Francesch Manzano
Josep Francesch Manzano
MTMarta Tajes
Marta Tajes
RPRaúl Ramos Polo
Raúl Ramos Polo
CECristina Enjuanes-Grau
Cristina Enjuanes-Grau
MJMaria del Mar Ras Jiménez
Maria del Mar Ras Jiménez
JCJosep Comín-Colet
Josep Comín-Colet
Iron deficiency (ID) is frequent in patients with heart failure (HF) and is correlated with adverse outcomes, yet its involvement in HF pathophysiology is not fully understood. Hyperactivity of the sympathetic nervous system (SNS) is the central feature of HF. We aimed to compare the effects of isoproterenol (ISO), a β-adrenergic agonist (SNS stimulation), with those of the iron chelator deferoxamine (DEF), to evaluate how β-adrenergic stimulation influences cardiac iron. In this study, H9c2 cardiac cells were challenged with ISO, DEF or both and several parameters related to iron metabolism were analyzed. In all cases, the cells decreased their intracellular iron levels. ISO induced alterations in key cardiac iron metabolism molecules that were, in most cases, comparable to those elicited by DEF, emphasizing the direct impact of β-adrenergic stimuli on iron metabolism and mitochondrial dysfunction. Nevertheless, unlike DEF, ISO triggered a shift in mitochondrial energy metabolism. These findings suggest that β-adrenergic stimulation, as a major component of neurohormonal activation, may contribute to the development of ID in cardiac cells, highlighting the importance of iron homeostasis and the need to further investigate iron dysregulation in this context.